Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qiagen ( (QGEN) ) has shared an announcement.
Qiagen has disclosed that Dutch market regulator AFM notified the company of a substantial shareholding in Qiagen by BlackRock, Inc., following a transaction dated 11 February 2026. According to the AFM register, BlackRock now holds a total capital interest of 10.68% and 11.80% of voting rights in Qiagen, via a range of subsidiaries and instruments including ordinary shares and contracts for difference.
The increase in BlackRock’s stake, largely held indirectly and combining real and potential holdings, underscores ongoing institutional investor interest in Qiagen’s equity. While Qiagen emphasizes it is not responsible for the accuracy of the AFM notification, the disclosed positions highlight a significant level of influence by one of the world’s largest asset managers over the company’s shareholder structure and governance dynamics.
The most recent analyst rating on (QGEN) stock is a Hold with a $50.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a Netherlands-based life sciences company specializing in sample and assay technologies for molecular diagnostics, applied testing, academic research and pharmaceutical development. Its shares are listed on multiple European exchanges as well as the NYSE and Swiss venues, giving it broad international investor exposure and liquidity.
Average Trading Volume: 2,029,889
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.42B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.